DeepSeek Slashes AI Model Pricing to Boost Adoption and Challenge Global Rivals 
Chinese Chip Stocks Surge on AI Boom and Domestic Tech Push 
U.S. Budget Airlines Seek $2.5 Billion Government Aid Amid Rising Jet Fuel Costs 
Lightelligence IPO Soars Over 400% in Hong Kong Debut Amid Rising AI Investment Demand 
DeepSeek V4 Launch Signals China’s Growing AI Independence with Huawei Chips 
Spirit Airlines Gains Key Creditor Support for $500M Bailout Deal 
WuXi AppTec Stock Surges on Strong Q1 Earnings and CRDMO Demand Growth 
Micro Systemation Reports Q1 Loss Amid Strategic Investments and Revenue Growth 
Brazil Blocks Prediction Market Platforms, Tightens Derivatives Trading Rules 
U.S. Sanctions Target Chinese Refinery Over Iranian Oil Purchases 
Judge Dismisses Elon Musk’s Fraud Claims Against OpenAI, Trial to Proceed on Remaining Allegations 
Novartis Q1 2026 Earnings Miss Expectations as Generic Competition Pressures Sales 
OpenAI Faces Revenue Pressure and User Growth Challenges Ahead of IPO 
SMC Corp Stock Surges as Palliser Capital Pushes for Major Share Buyback 
Advantest Stock Falls on Weak Outlook Despite Strong AI-Driven Results 
Sun Pharma to Acquire Organon in $11.75 Billion Deal to Boost Global Women’s Health Portfolio 
Kia Cuts EV Prices in Europe as Chinese Carmakers Intensify Competition 
NEW YORK, Feb. 19, 2016 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in the USDC for the District of Massachusetts on behalf of investors who purchased Tetraphase Pharmaceuticals Inc. (NASDAQ:TTPH) securities between March 5, 2015 and September 8, 2015.
Click here to learn about the case: http://docs.wongesq.com/TTPH-Info-Request-Form-1089. There is no cost or obligation to you.
The complaint alleges that Tetraphase and certain insiders issued materially false and misleading statements to investors. In particular, it is alleged that throughout the class period, Tetraphase made positive statements about the efficacy and potential for its drug Eravacycline to achieve approval by the FDA, despite knowledge that a pivotal portion of its IGNITE2 phase 3 clinical trial for Eravacycline would fail to achieve its primary endpoint of statistical non-inferiority compared to the antibiotic Levofloxacin.
On September 8, 2015, the Company announced that the pivotal portion of its IGNITE2 phase 3 clinical trial of Eravacycline did not achieve its primary endpoint. Following this news, shares of Tetraphase fell from a close of $44.78 on September 8, 2015, to a close of $8.36 per share on September 10, 2015—a loss of more than 80% in market value.
If you suffered a loss in Tetraphase you have until March 28, 2016 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email [email protected], by telephone at 212.425.1140, or visit http://docs.wongesq.com/TTPH-Info-Request-Form-1089.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
